Danaher (NYSE:DHR) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Danaher (NYSE:DHR) was downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, amidst mixed ratings from other brokerages.
• The company reported earnings of $1.89 per share for the latest quarter, surpassing expectations of $1.72 and showing a 4.4% revenue increase year-over-year.
• Insider activity includes Director Teri List selling 2,778 shares of Danaher stock, which represented an 11.81% decrease in their ownership.

Danaher (NYSE:DHR - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

Several other brokerages have also recently commented on DHR. Cowen reaffirmed a "buy" rating on shares of Danaher in a research report on Wednesday. Redburn Partners set a $220.00 price objective on Danaher in a report on Wednesday, October 8th. Barclays increased their price objective on Danaher from $225.00 to $250.00 and gave the stock an "overweight" rating in a report on Wednesday. Rothschild Redb lowered Danaher from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 8th. Finally, Wells Fargo & Company reiterated a "positive" rating on shares of Danaher in a report on Thursday. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $243.39.

Danaher Stock Performance

DHR opened at $223.03 on Friday. The firm has a market cap of $157.54 billion, a PE ratio of 45.99, a P/E/G ratio of 3.41 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $202.73 and a 200-day simple moving average of $198.36. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $258.23.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company's revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts predict that Danaher will post 7.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company's stock.

Institutional Investors Weigh In On Danaher

Institutional investors have recently added to or reduced their stakes in the stock. WFA of San Diego LLC acquired a new stake in Danaher during the second quarter valued at approximately $26,000. Howard Hughes Medical Institute acquired a new stake in Danaher during the second quarter valued at approximately $27,000. Sierra Ocean LLC boosted its holdings in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. TruNorth Capital Management LLC acquired a new stake in Danaher during the third quarter valued at approximately $28,000. Finally, Tripletail Wealth Management LLC acquired a new stake in Danaher during the third quarter valued at approximately $31,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.